# Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers

Source: https://onco.cc/trials/nct07553390/  
OnCo record `nct07553390` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests TROP-2-directed treatment; the registry reports that it is not yet recruiting.

## Summary

The registry lists NCT07553390 as not yet recruiting, last updated 2026-08-19. Enrolment is 60 planned participants, an estimate. Interventions: TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells, Trastuzumab deruxtecan (T-DXd), Rimiducid. Primary measures include Safety and Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-10-06
- Registry id: NCT07553390
- Phase: 1
- Setting: Phase 1b Study Of Allogeneic CAR TROP2/IL15 Transduced TGFBR2 KO CB NK-Cells (TRICK-NK) In Combination With Trastuzumab Deruxtecan (T-Dxd) In Treatment-Refractory Breast Cancers
- Sponsor: M.D. Anderson Cancer Center

## Sources

- ClinicalTrials.gov NCT07553390: https://clinicaltrials.gov/study/NCT07553390

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- targets: [TROP2](https://onco.cc/targets/trop2/)

---
JSON: https://onco.cc/api/v1/entities/nct07553390.json